Jefferies analyst Anthony Petrone added Haemonetics to his firm’s Franchise Picks list citing the recent pullback in the shares and his view that the company is still well positioned to see “substantial” earnings upside as the NexSys cycle plays out. He believes a stock price of $150-plus is likely over time and keeps a Buy rating on Haemonetics with a $125 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.